Miltenyi, 130-050-301, CD19 MicroBeads, human

Background information
As a B cell lineage marker, the CD19 antigen is expressed from the early pro-B cell stage to the B cell lymphoblast stage, but the expression is down-regulated upon B cell maturation to plasma cells. The CD19 antigen is further expressed on most malignant B cells and on a subset of follicular dendritic cells.

Downstream applications
Isolated CD19+ B cells were used for studies on immunoglobulin production, such as IgE synthesis1, 2 and secretion3, chemotaxis assays4, or mixed lymphocyte reactions. Positively selected CD19+ B cells were also used for molecular studies such as gene expression profiling.5 For the analysis of minimal residual diseases in B cell malignancies, enrichment of B cells increases the sensitivity of detection.6

Columns
For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.

Overview
CD19 MicroBeads were developed for positive selection or depletion of CD19+ B cells from different cell sources such as human PBMCs, bone marrow, lymphoid tissues, or cell cultures.